Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
U Vitolo, JF Seymour, M Martelli, G Illerhaus, T Illidge, E Zucca, E Campo, M Ladetto
ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2016
UV has reported global advisory boards for lymphoma for Roche and Janssen; lectures and educational activities for Roche, Janssen, Gilead, Celgene and Takeda; research sponsored by Celgene. JFS has reported research funding from Abbvie and Janssen; advisory boards for Abbvie, Celgene, Genentech, Gilead, Infinity, Janssen, Roche and Takeda; speakers' bureau for Abbvie, Celgene, Gilead, Janssen and Roche; honoraria from Abbvie, Celgene, Gilead, Janssen, Roche and Takeda; travel support from Celgene and Roche; and consultancy fees from Celgene, Roche and Takeda. TI has reported speakers' bureau for Takeda and Roche; research sponsored by Merck, Roche and Millennium. EZ has reported advisory honoraria and/or support of investigator-initiated studies (for the institution) from Celgene, Johnson and Johnson/Janssen, Gilead, Mundipharma, Roche and Bayer. ML has reported honoraria from Celgene, Janssen-Cilag, Roche, Amgen, Mundipharma and Teva; research contracts from Celgene, Pfizer, Mundipharma and Roche; funds received from Amgen, Roche and Takeda. GI, EC and MM have declared no potential conflicts of interest.